Overview

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

Status:
Completed
Trial end date:
2012-03-03
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) of OSI-906 in combination with erlotinib
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Erlotinib Hydrochloride